Industries: Biotech & Pharma
Funding stage: Series A (1 M EUR - < 5 M EUR) Founded: 2012 Employees: From 6 to 10
Business model: Development & Manufacturing, Other types of licence Target: Business
Biotech spin-out from Princeton University focused on developing the next-gen cancer immunotherapy and targeted therapies. Our proprietary technology enables precise targeting of dendritic cells in vivo to trigger an innate and adaptive response against cancer.
Minority stake unknown %
Investors: CAIXA CAPITAL RISC, PRIVATE BUSINESS ANGEL
Source: Press releases , newsletters & platforms , company websites , annual reports & accounts , regulatory body sites & stock exchanges
We are continually updating our list of new startups so please let us know if you have recently started one.